Zemek, Rachael M. http://orcid.org/0000-0002-0976-6163
Fear, Vanessa S.
Forbes, Cath
de Jong, Emma
Casey, Thomas H. http://orcid.org/0000-0002-3522-005X
Boon, Louis
Lassmann, Timo http://orcid.org/0000-0002-0138-2691
Bosco, Anthony
Millward, Michael J.
Nowak, Anna K. http://orcid.org/0000-0002-9317-9526
Lake, Richard A.
Lesterhuis, W. Joost http://orcid.org/0000-0002-2718-276X
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1103980)
Article History
Received: 11 September 2019
Accepted: 16 January 2020
First Online: 1 April 2020
Competing interests
: A patent application pertaining to aspects of this work has been filed by R.M.Z., W.J.L., R.A.L., and A.B. (PCT/AU2019/050259, “Method for immunotherapy drug treatment”). A.K.N., M.J.M., A.B., R.A.L., and W.J.L. have received research funding and consultancy fees from Douglas Pharmaceuticals. W.J.L. has received research funding from AstraZeneca and consultancy fees from Merck Sharp & Dohme. A.K.N. declares consultancy or advisory board membership for Boehringer Ingelheim, Bayer Pharmaceuticals, Roche Pharmaceutics, Merck Sharp Dohme, Pharmabcine, Atara Biotherapeutics and Trizell, and research funding from AstraZeneca. M.J.M. has served on advisory boards for Merck Sharp & Dohme, Bristol-Myers Squibb, Roche, and AstraZeneca.